FDA Approves Celcuity’s REVTORPYK for HR+/HER2-, PIK3CA Wild-Type Advanced Breast Cancer
The FDA has approved Celcuity‘s REVTORPYK (gedatolisib) for HR+/HER2-, locally advanced or metastatic breast cancer without a PIK3CA mutation, following progression on or after at…